In today’s Pharmaceutical Executive Daily, we cover major leadership changes at Novo Nordisk, Kenvue’s request for the FDA to reject a petition calling for Tylenol label changes, and industry insights from Bob Mauch on building a stronger, more resilient pharmaceutical supply chain.
Novo Nordisk faces significant board changes and stock declines as it navigates governance conflicts with its foundation, aiming for future growth.
In this video discussion with Pharmaceutical Executive, Michael J. Hennessy Jr., chairman and CEO of MJH Life Sciences, and Jason Brown, CEO of BPD Healthcare, discuss how the deal came together and what it means for healthcare executives navigating an increasingly complex marketplace.
Recent research shows mRNA COVID vaccines significantly enhance survival rates in cancer patients undergoing immunotherapy, potentially revolutionizing cancer treatment.
Explore CEO insights on decision-making in manufacturing, focusing on risk management, packaging challenges, and strategies for product safety and quality.
Clinical trial sites face persistent payment delays and complex processes, risking their viability and impacting drug development. Solutions prioritize transparency and flexibility.
At HLTH 2025, the entrepreneur announced a collaboration between Cost Plus Drugs and President Trump’s TrumpRx platform aimed at improving transparency, reducing drug costs, and reshaping how Americans access their prescriptions.
The collaboration will focus on enhancing cancer therapies through next-gen immuno-oncology and ADC treatments for solid tumors.
“This is about building a powerful bridge between the science that transforms lives and the systems that deliver that transformation,” said Michael J. Hennessy Jr., MJH Life Sciences chairman and CEO, of the BPD Healthcare acquisition.
Jesse Mendelsohn, executive vice president at Model N, discusses the broader issues impacting drug prices.
Peptilogics Founder and CEO, Jonathan Steckbeck, explained that PLG0206’s membrane-active mechanism enables it to destroy both active and dormant biofilm bacteria overcoming a key limitation of traditional antibiotics.
Many of the biodiversity risks associated with pharmaceutical production occur beyond the direct operational control of pharmaceutical businesses, whic means that addressing them requires a collaborative, systemic approach to sustainability.
Cencora CEO Bob Mauch discusses the lessons learned during his first year at the helm—and tackling a complex future for pharma distribution.
The proposed change would add a warning about an increased risk of autism, despite a lack of scientific evidence connecting the medication to the condition.
The company will hold an Extraordinary General Meeting in November to elect new members.
In today’s Pharmaceutical Executive Daily, we cover Merck’s $70 billion expansion of U.S. operations, the FDA’s latest approvals for Novo Nordisk’s Rybelsus and Roche’s Gazyva, and a new digital health partnership between Amazon and WeightWatchers bringing prescription weight-loss drugs directly to consumers.
An analysis of pricing data for 12 high-revenue drugs from Medicare Part B and Part D compares US wholesale acquisition costs with the lowest prices in reference countries under the most-favored nation model.
Amid converging pharma pricing trends, such as those triggered by the Inflation Reduction Act, companies must adopt novel operational practices and strategic approaches in line with new parameters for success across a product’s lifecycle.
Galapagos scales back its cell therapy business to enhance efficiency and focus on transformative opportunities, impacting over 365 employees globally.
Sanofi's Tzield gains FDA's expedited review, promising rapid access to innovative treatment for type 1 diabetes and addressing significant medical needs.
The new partnership aims to transform cold chain logistics for life sciences, creating a connected air transport network designed to ensure temperature integrity, regulatory compliance, and faster delivery of critical therapies.
A blueprint for how companies can move from isolated pilots toward effective AI implementation.
Jesse Mendelsohn, executive vice president at Model N, explains the pros and cons of continuing to pursue DTC programs once the government-run program launches.
Artax Biopharma’s CEO Rob Armstrong explains recent shifts in autoimmune R&D before discussing his leadership style.
Peptilogics Founder and CEO, Jonathan Steckbeck noted that advances in peptide design and safety have positioned the field to address drug-resistant pathogens more effectively.
The importance for pharma in recognizing integrated data sources as necessary infrastructure—not just a competitive edge.
In today’s Pharmaceutical Executive Daily, we cover the FDA’s creation of a new National Priority Voucher Program, the market reaction to President Trump’s remarks on GLP-1 drug prices, and how autonomous AI is transforming omnichannel marketing in pharma.
Merck invests $70 billion in US operations, launching a $3 billion manufacturing site in Virginia to enhance drug production and create jobs.
Tips for turning transactional outreach into a trusted working relationship.
The two companies are the latest to join the DTC offerings to address high drug prices.
